March 24, 2021
Japan’s Ministry of Health, Labor and Welfare (MHLW) approved a throng of new medicines on March 23, including Incyte Biosciences’ cancer drug Pemazyre (pemigatinib) and Bayer Yakuhin’s tumor-agnostic agent Vitrakvi (larotrectinib). A selective fibroblast growth factor receptor (FGFR) inhibitor, Pemazyre...read more